Shares of Corcept Therapeutics jumped 12.4% in pre-market trading to $91.17 on November 2, the day before the company is set to report third-quarter results. The rally caps a week dominated by two catalysts: strong clinical data released October 26 and rising expectations for tomorrow's earnings call. For investors, the question is whether the stock's momentum is running ahead of the fundamentals or simply catching up.
• A Cancer Trial Beat Expectations, and the Market Noticed
Corcept's three-drug combination showed a 59% tumor-shrinkage rate and median progression-free survival of 7.2 months in 95 women with platinum-resistant ovarian cancer — a form of the disease that has stopped responding to standard treatment.
That 59% response rate far outpaced the 37% achieved by the two-drug regimen and 30% by chemotherapy alone in the company's larger Phase 3 study; 88% of patients in the trial were alive at six months versus 77% on chemo alone. The data suggest adding a third drug could meaningfully improve outcomes, which would broaden the market for Corcept's treatment.
• A Billion-Dollar Revenue Year Is Now Within Reach
In Q2, Corcept posted revenue of $256.1 million — up 32% year-over-year — and raised full-year 2026 guidance to $1.1–$1.2 billion.
Over 1,300 patients had already started treatment with the newly approved cancer drug since its March FDA clearance.
Analysts expect Q3 earnings per share of roughly $0.79 on revenue near $324 million. A beat tomorrow could justify further upside; a miss at this elevated price would sting.
• The Stock Still Sits Well Below Its 52-Week High
Corcept's one-year range runs from a low of $28.66 to a high of $126.38 , meaning even after today's pop the stock trades about 28% below its peak. Yet it carries a high earnings multiple — the price relative to per-share profits — making it sensitive to any disappointment.
• The Trial Has Limits Investors Shouldn't Ignore
The trial lacked a control group receiving the same treatment without the cancer drug, so the favorable numbers were compared across separate studies with different patient populations. That makes the results encouraging but not definitive. Corcept expects the data to strengthen its place in national treatment guidelines, with full results due at a medical conference next year. Until then, investors are pricing in promise — a bet that could pay handsomely or prove premature once tomorrow's numbers land.